Working matrix

We go for an innovative approach in healthcare technology as current models have turned inefficient. Towards this new approach, HealthTIES has developed a matrix formed of major disease areas and technology platforms in order to give the best answer to 21st century challenges.

To create a proper environment for facing the challenges of the 21st century in we have built the Healthcare Technology Specialization Matrix (HTSP), which confers an innovative approach in the working methodology.

HealthTIES partners have identified the four major disease areas related with an increasingly ageing population: cardiovascular, cancer, neurodegenerative and immunology and infectious diseases. HealthTIES partners have a strong scientific and technological track record and the medical centres in the HealthTIES regions are strong in clinical research and patient care in the four disease areas.

Along with these major disease areas, we focus on three technological methodologies that open up exciting new opportunities for early and accurate diagnosis, targeted therapy, more appropriate and effective treatments reduction of side effects and societal costs.

The technology platforms are:

  • Molecular technology, including high throughput DNA sequencing and biophysics
  • Imaging, including synchrotron, light and clinical imaging and bioengineering
  • Drug design, development and delivery, including chemistry and early phase clinical trials

HealthTIES applies these technologies to the four major disease areas and builds a working matrix (HTSM), as a useful working tool for analysing our regions, finding synergies and develop best practices towards the speeding up diagnosis, cost-effective treatments and putting in place early screening programs for the reduction of mortality rates.

General first thoughts of the HealthTIES Consortium on areas for improvement at the intersections of disease areas and technology platforms are: Prevention through risk factor identification, secondary prevention coupled with community-based care and treatment and acute treatment. More specifically, the Atherosclerosis assessment should be improved by targeted imaging techniques (at intersection of Cardiovascular and Imaging). Furthermore, activities in rare cancers should be coordinated and nanoparticle technology will allow superior resolution of conventional methods to diagnose and treat cancer. Therapies for Alzheimer’s disease should be improved by the use of biomarkers that identify abnormal brain structure or function. In addition, imaging techniques will play a key role in monitoring immune response in patients receiving immunotherapy